← brief for 2026-09-03 · Slowing decline

Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.

Article No results yet Peer reviewed

Key takeaways

This is a review article, not a new study. It gathers what is known about GLP-1 drugs, the semaglutide family, for people with diabetes and kidney disease. Its argument is that even with blood pressure drugs and SGLT2 inhibitors, a lot of heart and kidney risk is left over, and these drugs go after the metabolic problem driving it. A review runs no experiment of its own, so there are no new results here.

Who did this work

Kim Y · Lee EY · Korean Diabetic Kidney Disease Study Group

Source

Article · PubMed, the drug frontier · 2026 Sep 1
https://pubmed.ncbi.nlm.nih.gov/42682157/